Discover 146 paid clinical trials in Wichita, Kansas. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 146
Active & Responsive
GATE-251 or Placebo for the Reduction of Symptoms of Major Depressive Disorder
for
Major Depressive Disorder
Location: 24 recruiting locations
Sponsor: Syndeio Biosciences, Inc
Sex: All
Age: 18 - 64
Code: NCT06547489
Phase2, Recruiting
Active & Responsive
SELUTION 4 De Novo Small Vessel IDE Trial
for
Coronary Artery Disease
Location: 36 recruiting locations
Sponsor: M.A. Med Alliance S.A.
Sex: All
Age: 18+
Code: NCT05946629
Recruiting
Active & Responsive
Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening
for
Lung Cancer Diagnosis
Location: 36 recruiting locations
Sponsor: Freenome Holdings Inc.
Sex: All
Age: 50+
Code: NCT06122077
Recruiting
Active & Responsive
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis
for
Moderately to Severely Active Ulcerative Colitis
Location: 49 recruiting locations
Sponsor: Hoffmann-La Roche
Sex: All
Age: 16 - 70+
Code: NCT06588855
Phase3, Recruiting
Active & Responsive
BradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenT
Get alerts for new trials in your area by subscribing now
Active & Responsive
The REBALANCE Study - a Prospective, Multicenter, Randomized, Pivotal Study of the May Health System
for
Polycystic Ovary Syndrome, Infertility, Female
Location: 18 recruiting locations
Sponsor: May Health
Sex: Female
Age: 18 - 40
Code: NCT06206746
Recruiting
Active & Responsive
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
for
Moderately to Severely Active Crohns Disease
Location: 79 recruiting locations
Sponsor: Hoffmann-La Roche
Sex: All
Age: 16 - 70+
Code: NCT06819878
Phase3, Recruiting
New
A Study of Weekly Oral Ecnoglutide (VRB-101) in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities